ABT vs SYK
Abbott Laboratories vs Stryker Corporation — AI-powered side-by-side comparison
ABT
Abbott Laboratories
66
Buy
VS
SYK
Stryker Corporation
59
Buy
| Metric | ABT | SYK |
|---|
| AI Score |
66
|
59
|
| Price |
$114.70
|
$329.92
|
| P/E Ratio |
37.34×
|
33.98×
|
| ROE |
12.5%
|
14.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
56.8%
|
65.2%
|
| Debt / Equity |
0.64×
|
0.62×
|
| Dividend Yield |
2.1%
|
1.1%
|
| RSI (14) |
78.4
|
44.6
|
| Beta |
0.581
|
0.771
|
| Expected Upside |
+0.6%
|
+13.1%
|
AI Committee View
Current Innellis committee reasoning for ABT versus SYK.
ABT leads by 7 points.
ABT scores 66/100 (Buy) versus SYK at 59/100 (Buy).
ABT Committee View
75% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- RSI at 85 is in overbought territory — Technical
- Weekly RSI at 83 -- overbought on the larger timeframe too — Technical
SYK Committee View
60% agreement
5 analysts
Positive signals support the current rating — eps growing 27.7% yoy. The committee sees sufficient evidence to maintain the constructive view.
Bull Case
- ROE of 16.4% shows genuine earnings power backing the valuation — Value
- EPS growing 27.7% YoY — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- P/E of 35.2 is moderate-to-rich — Value
- Price-to-book of 6.0x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical